The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

When should we consider allo-HSCT in a patient with ALL? And when not?

During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub spoke to Sebastian Giebel, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, PL. We asked, When should we consider allogeneic hematopoietic stem cell transplantation (allo-HSCT) in a patient with ALL? And when not?

When should we consider allo-HSCT in a patient with ALL? And when not?

Allo-HSCT is a very effective method of treatment for ALL, however, it is also associated with a significant risk of mortality. In this video, Giebel discusses tailoring treatment paradigms according to Philadelphia chromosome subtypes and high-risk karyotypes. He also touches upon ongoing studies looking at second- or third-generation tyrosine kinase inhibitors and chimeric antigen receptor (CAR) T-cell therapies that could offer new opportunities for patients with ALL in the future.

 

Share: